To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the percentage of MPO-positive blast (high [X50%] and low (o50%)). Complete remission rates were 85.4% in the former and 64.1% in the latter (P ¼ 0.001). The overall survival (OS) and the disease-free survival (DFS) were significantly better in the high MPO group (48.3 vs 18.7% for OS, and 36.3 vs 20.1% for DFS, Po0.001, respectively). Multivariate analysis showed that both karyotype and the percentage of MPO-positive blast cells were equally important prognostic factors. The high MPO group still showed a better survival even when restricted to the intermediate chromosomal risk group or the patients with normal karyotype (Po0.001). The OS of patients with normal karyotype in the high MPO group was almost equal with that of the favorable chromosomal risk group. The percentage of MPO-positive blast cells is a simple and highly significant prognostic factor for AML patients, and especially useful to stratify patients with normal karyotype.
Introduction
Myeloperoxidase (MPO), a microbicidal protein in the primary granules, is the hallmark enzyme of the myeloid lineage. Expression of the MPO gene is specific for myeloid precursors and their leukemic counterparts, and transcription of the MPO gene is turned on only during the late myeloblast and promyelocyte stages of myeloid maturation. [1] [2] [3] Thus, MPO gene is exclusively expressed in immature myeloid cells with downregulation of gene expression during myeloid maturation, although the enzyme activity can be preserved in mature neutrophils. The diagnosis of acute myeloid leukemia (AML) is easy if more than 3% of blast cells are confirmed to be cytochemically MPO positive, although most blast cells are MPO negative in M0, M5, and M7 subtypes by the FrenchAmerican-British (FAB) classification. [4] [5] [6] [7] [8] [9] Thus, the percentage of MPO-positive blast cells has generally been considered to be very important for the diagnosis but not for the prognosis of AML, although a few studies have previously shown the prognostic significance of MPO in AML. [10] [11] [12] [13] Other than the clinical features such as age or performance status, karyotypes of leukemia cells are considered as the most important and independent prognostic factor for AML. The importance of cytogenetics was clearly shown in a previous MRC report, 14 indicating that t(8;21), t (15;17) , and inv(16) predicted a favorable outcome and complex karyotype, À5, del(5q), À7, and abnormalities of 3q defined an adverse group with poor prognosis. However, this system did not provide a further framework to stratify treatment for two-thirds of their patients, who were classified as an intermediate group with other cytogenetic abnormalities or without abnormalities. In the present study, we assessed the percentage of MPO-positive blast cells as a prognostic factor for AML, in comparison with other prognostic factors including chromosomal karyotypes.
Patients and methods

Patients
A total of 611 patients with newly diagnosed AML in 41 hospitals (age 15 years or older, M3 was excluded because of the stratification by all-trans retinoic acid therapy) were registered to the Japan Adult Leukemia Study Group (JALSG)-AML92 study from December 1991 to August 1995. Details of the protocol and major results of this trial were previously reported. 15 Briefly, the protocol consisted of behenoyl cytarabine (BHAC)-and daunorubicin-based induction therapy (with or without etoposide), and three courses of consolidation therapy (comprised of mitoxantrone, daunorubicin or aclarubicin, plus BHAC) followed by six courses of maintenance therapy. The clinical or laboratory data of each patient were obtained through the clinical report forms of the JALSG-AML92 study.
Morphological diagnosis and MPO-positive rates of blast cells
The committee for morphological diagnosis reviewed slides of the peripheral blood and bone marrow at diagnosis, according to the FAB classification. [4] [5] [6] [7] [8] [9] The trilineage dysplasia (TLD) in the presence of leukemia blasts was also evaluated according to the diagnostic criteria as previously reported. 16 Three members (TM, KK, and YM) assessed the percentage of MPO-positive blast cells on MPO-stained bone marrow smears by the diaminobenzidine method 17 without clinical information of the patients at the time of diagnostic review. The investigators carefully observed blast cells in May Grunwald-Giemsa-stained smears before assessing the MPO positivity among blast cells. The MPO-positive blast cells were identified depending on localized, coarse granular, or fine scattered patterns of the MPO activity in the cells with high nuclear/cytoplasm ratio. Promyelocytes were distinguished by their very strong and diffuse distribution of MPO activity over the nuclei. The percentage of MPO-positive blast cells was an average of the values gained by the investigators and was reassessed carefully when the variation of them among the investigators exceeded 10%. The interclass correlation coefficiency of the percentage of MPO positive blasts among three observers was 0.985 and the Spearman correlation coefficients between two of three observers were 0.946, 0.960, and 0.962.
Cytogenetic analysis
Cytogenetic analysis was performed in the laboratories of participating hospitals or some authorized laboratory companies. The karyotypes were collected through the clinical report forms of JALSG-AML92. 
Risk factors
Some other known risk factors on prognosis such as age (o50 vs 50 years or more), white blood cell (WBC) count at diagnosis (o20 000, 20 000 or more), the presence of TLD phenotype, and FAB subtypes (M2 or M1, M4, M5 or M0, M6, M7) were also evaluated.
Statistical analysis
We analyzed the complete remission (CR) rates by risk factors: the w 2 test was used for nominal scale data such as the FAB subtypes, while the Cochran-Armitage trend test was used for ordinary scale data such as chromosomal risk group. CR was defined as less than 5% of blast cells in normocellular marrow and evidence of normal maturation of other marrow cells. Overall survival (OS) is the time from entry to death, and disease-free survival (DFS) is the time from CR to relapse or death. The OS and DFS by each risk factor were examined by the Kaplan-Meier method, and the difference of OS and DFS rates was analyzed using the log-rank test. Furthermore, the simultaneous effects of risk factors on CR were analyzed using multivariate logistic regression analysis, and those on OS and DFS were analyzed using Cox's proportional-hazard model. All statistical analyses were performed using SAS software. 18 
Results
MPO-positive rates of blast cells
Both MPO-stained smears and the results of karyotype analysis were informative in 491 patients. Table 1 shows the patients' characteristics. First, patients were categorized into four groups according to MPO-positive percentage among the leukemic blast cells; 141 patients with less than 25% (group I), 76 patients with 25-49% (group II), 44 patients with 50-74% (group III), and 230 patients with more than 75% (group IV). As shown in Figure 1 , M1, M2, and M4 were major FAB subtypes in all the MPO categories and M0, M5a, and M7 were found in only group I because of their definitions.
Chromosomal risk group
Based on the karyotypes of leukemia cells at diagnosis, 88 patients were placed in the favorable risk group, and 40 patients were classified in the adverse risk group (Table 1) . The intermediate risk group consisted of 363 patients, 235 of whom showed normal karyotype.
CR rate
CR was confirmed in 59.6% of group I, 72.4% of group II, 86.4% of group III, and 85.2% of group IV by blast MPO positivity. Thus, the degree of MPO-positive percentage among blast cells was significantly related to the response rate to chemotherapy (P ¼ 0.001). This was not due to the unevenly distributed FAB subtypes, because the results were the same when the analysis was restricted to the patients with M1, M2, and M4; CR rates were 63.4% in group I, 71.4% in group II, 85.4% in group III, and 84.9% in group IV (P ¼ 0.001). If we 
OS and DFS
All factors assessed were significant for OS, but only factors other than age and TLD were for DFS by the univariate analysis (Table 2) . However, by the multivariate analysis the chromosomal risk group (favorable vs adverse), MPO, WBC count, and age were significant on OS (Po0.001) ( Table 3) . Despite the exclusion of the AML M3 subtype, there was a significant difference in OS among the chromosomal risk groups, similar to the original MRC study (Figure 2 ). The OS rates at 4 years were 9.7% in the adverse group, 36.3% in the intermediate group, and 57.6% in the favorable risk group (Po0.001). The DFS rates at 4 years were also different (P ¼ 0.001) (5.3, 31.2, and 40.8%, respectively). The groups by the MPO positivity also showed a significant difference in OS. The OS rates at 5 years were 20.0% in group I, 27.1% in group II, 51.4% in group III, and 50.1% in group IV (P ¼ 0.001). The DFS rates at 5 years were also different (16.1, 24.6, 28.7, and 39.7%, respectively, P ¼ 0.001). Then, we combined groups I and II as the low MPO group, and groups III and IV as the high MPO group. As shown in Figure 3a , there was a significant difference in OS between the low MPO group and the high MPO group (18.7 and 48.3% at 5 years, respectively, Po0.001). This was not due to the uneven distribution of FAB subtypes, although almost all prognostically poor M0, M5, and M7 cases were in the low MPO group. Even when the analysis was restricted to M1, M2, and M4 patients, a similar difference of OS was observed between two groups (Po0.001, Figure 3b ).
MPO subgroups in the chromosomal risk groups
Interestingly, 83 of 88 patients with favorable chromosomal risk belonged to the high MPO group, while 33 of 40 patients with adverse chromosomal risk were in the low MPO group (Table 4) . There was an obvious trend that the percentage of MPO-positive blast cells decreased as the chromosomal risk worsened (Po0.001). The intermediate chromosomal risk group consisted of 363 patients (74% of all patients) and was distributed evenly between low and high MPO. There was also a highly significant Figure 1 Distribution of FAB subtypes by MPO-positive rates of blast cells. M1, M2, and M4 were major FAB subtypes in all the MPO categories and M0, M5a, and M7 were found in only group I. Figure 3c ). The intermediate chromosomal risk group included 235 patients (47.9% of whole AML patients) with normal karyotype. Again, the same difference in OS between the low and high MPO groups was clearly shown among these patients (Figure 3d ). The OS rate at 5 years was 15.2% in the low MPO group and 48.4% in the high MPO group with normal karyotype (Po0.001). Of note, the OS of the patients with normal karyotypes in the high MPO group was almost equal with that of the favorable chromosome risk group (Figure 4) .
Discussion
It has previously been suggested that the percentage of MPOpositive blast cells has an impact on clinical outcomes of AML. [10] [11] [12] [13] The ECOG study showed that patients with less than Blast MPO Positivity Predicts AML Prognosis T Matsuo et al 50% MPO-positive blasts showed a low CR rate (52.6%), while patients with more than 50% MPO-positive blasts had a significantly better CR rate (85.3%) in the AML M1 subtype (P ¼ 0.003).
11 A similar significant difference in CR was also shown in the M2 subtype. 12 Despite these data, systematic investigations on MPO in whole AML as a prognostic factor have not been performed in a large population with a long follow-up period. Recently, JALSG reported a significant importance of the percentage of MPO-positive blast cells for survival in a large population. 13 In a similar feature, the percentage of Sudan Black-positive blast cells, less than 50% or more than 50%, was also shown to be prognostically important for AML in a large population. 19 However, the relation between the percentage of MPO-positive blast cells and chromosomal risk groups, which have been recognized as the most valuable prognostic factor in AML, was not studied. We assessed the significance of percentage of MPO-positive blast cells in AML patients of the JALSG-AML92 study, in relation to chromosomal risk groups.
The OS rate of all patients at 5 years was 36.9% in this study. The categories by cytogenetics in our study without M3 subtype also showed a significant difference among the three groups (Figure 2) , similar to the MRC study.
14 It is also similar to the MRC results that both the adverse and favorable chromosomal risk groups were relatively small in size and the intermediate risk group was a major group. The intermediate chromosomal risk group was 1072 (66.5%) of 1612 patients in the MRC study and 363 (73.9%) of 491 patients in the present study. Our study indicates the prognostic significance of percentage of MPOpositive blast cells in AML, in general, and that it is still significant even when the analysis was restricted to patients with the intermediate chromosomal risk or normal karyotype. This is a very important observation because there is no framework at present for these patients to be stratified in treatment. We thus believe that the percentage of MPO-positive blast cells is the most simple and useful factor to predict a prognosis of AML patients in this category. The analysis of MPO-positive blast cells is not only time-saving but also cost-saving method compared with the molecular analysis of abnormal genes.
It is unknown why the percentage of MPO-positive blast cells has an impact on the clinical outcome of AML. The MPO activity may only be a result of myeloid differentiation and MPO-positive blast cells may be more differentiated than MPOnegative blast cells. It is a general consensus that the MPOnegative M0 subtype with immature features showed a disappointing clinical outcome, 20 compared to the MPOpositive M1 subtype. Thus, the MPO activity may reflect the maturation of leukemia blasts, and it may be easier to eradicate the more differentiated blast cell population by chemotherapy, compared to the immature population. Therapeutic resistance in AML is well known to be associated with rapid drug efflux mediated by multidrug-resistance glycoprotein MDR1 and other proteins (multidrug-resistance-associated protein 1 and lung-resistance protein). [21] [22] [23] [24] Furthermore, a recent study showed a significantly higher resistance rate in patients with increased MDR1 expression as well as in those patients with decreased reactivity to MPO. 25 Thus, it is possible that the MPOpositive rate of blast cells is associated with drug-resistance mechanisms.
It is also possible that blast MPO activity is related to the rearrangement of the regulatory and coding regions of various transcription factor genes implicated in the leukemogenesis. 26 A recent study showed the difference in the promoter region of the MPO gene related to the MPO activity: the SpSp genotype with a high level of MPO mRNA and MPO protein was presented in about 80% of AML M3 and M4 subtypes. 27 The ratio of SpSp to other genotypes, SpN or NN, in these leukemias was 2.6-fold higher than in the general population. A possibility was suggested that MPO-generated radicals increased the risk of DNA crosslinking, mutation or strand breakage to leukemic evolution. However, these studies have not provided an explanation for the relation between MPO and response to chemotherapy. [1] [2] [3] 27 Further investigations may disclose some relations between MPO and many other genetic alterations with important prognostic implications.
In contrast to the above, it is also possible that abundant MPO itself in leukemia cells is a cause of this prognostic difference. It was recently reported that a drug-induced cytotoxicity correlated with amount of MPO in HL-60, an AML cell line. 28 More recently, it was shown that H 2 O 2 -induced apoptosis is mediated by MPO in HL-60. 29 H 2 O 2 has been assumed to be an intracellular mediator in the toxicity of chemotherapy. They showed that H 2 O 2 induced apoptosis in the HL-60 with high MPO activity, but not in the K562 chronic myeloid leukemia cell line without MPO protein. Interestingly, the HL-60 cells no longer underwent apoptosis in responding to H 2 O 2 after they were grown to high passage number and lost their MPO. Then, the existence of MPO within the leukemia cells would be a disadvantage for them when chemotherapy was administered. If MPO of leukemia blasts itself increases the response to There was a trend that the MPO-positive rates of blast cells decreased as chromosomal risk worsened (Po0.001). High MPO group with normal karyotype (n=130)
Favorable chromosomal risk group (n=88)
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Figure 4
Comparison of OS between the favorable chromosomal risk group and high MPO with normal karyotype. This is a comparison between the favorable chromosomal risk and normal karyotype in the patients with high MPO, because most of the favorable chromosomal risk group showed high MPO.
Blast MPO Positivity Predicts AML Prognosis
T Matsuo et al chemotherapy, differentiation-inducing agents that trigger the induction of MPO in blasts may enhance the effect of chemotherapy. Such a trial, for example, could be performed on patients categorized in the low MPO group. Most of the patients with the favorable chromosomal risk were in the high MPO group and most of the patients with the adverse chromosomal risk were in the low MPO group, although the percentage of MPO-positive blast cells varied from low to high in the patients with normal karyotype. Furthermore, the clinical outcomes of the favorable chromosomal group and the high MPO patients with normal karyotype were quite similar in this study. These facts suggested a possibility that the impact of chromosomal risk on clinical outcome might be related, at least in part, to blast MPO contents as a result of various genetic events. If the quantitative amount of MPO in blast cells gave a direct impact on the effect by chemotherapy, it will provide a new insight for therapy and classification of AML.
